Abivax SA American Depositary Shares (ABVX)vsJohnson & Johnson (JNJ)
ABVX
Abivax SA American Depositary Shares
$124.33
+4.62%
HEALTHCARE · Cap: $10.83B
JNJ
Johnson & Johnson
$255.88
-3.66%
HEALTHCARE · Cap: $615.36B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 1990327% more annual revenue ($97.93B vs $4.92M). JNJ leads profitability with a 21.5% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 57/100 (C).
ABVX
Avoid33
out of 100
Grade: F
JNJ
Buy57
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 35.2% year-over-year
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 28.6%
Generating 3.4B in free cash flow
Areas to Watch
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
Trading at 20.2x book value
Moderate valuation
Expensive relative to growth rate
Earnings declined 1.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABVX
The strongest argument for ABVX centers on Revenue Growth. Revenue growth of 35.2% demonstrates continued momentum.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 28.6%.
Bear Case : ABVX
The primary concerns for ABVX are EPS Growth, Profit Margin, Piotroski F-Score.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
ABVX profiles as a hypergrowth stock while JNJ is a mature play — different risk/reward profiles.
JNJ carries more volatility with a beta of 0.23 — expect wider price swings.
ABVX is growing revenue faster at 35.2% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (57/100 vs 33/100), backed by strong 21.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abivax SA American Depositary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies for chronic inflammatory diseases and viral infections. Its lead candidate, ABX464, is in advanced clinical trials targeting ulcerative colitis, utilizing a novel approach that integrates antibody-mediated therapies with proprietary compounds. Backed by a robust pipeline and an experienced scientific team, Abivax is strategically positioned to meet substantial unmet medical needs, making it an attractive prospect for institutional investors aiming to engage with the growing immunotherapy landscape.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?